Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. Design studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results

COVID 19 hospitalized meta-analysis

COALIZAO ACTION
  NCT04394377		 RCTanticoagulant, curative dosecontrolCOVID 19 hospitalizedsome concern
311/304 inconclusive

    COVID-19 mild to moderate meta-analysis

    ATTACC, ACTIV-4a, and REMAP-CAP (noncritically ill patients)
          NCT02735707    		 RCTanticoagulant, curative dosecontrolCOVID-19 mild to moderatesome concern
    		1190/1054 conclusif
    • demonstrated 27 % increase in clinical improvement (28-day) (PE) with a moderate degree of certainty due to some concern in risk of bias
    atypical endpoints without correspondence with those of the others trials
    RAPID (Sholzberg)
          NCT04362085    		 RCTheparin at therapeutic dosestandard of careCOVID-19 mild to moderatesome concern
    		228/237 suggested
    • suggested 78 % decrease in deaths,death D28 with a moderate degree of certainty due to some concern in risk of bias
    • inconclusive 31 % decrease in clinical deterioration (PE) with a moderate degree of certainty due to some concern in risk of bias

    COVID-19 severe or critically meta-analysis

    INSPIRATION
          NCT04486508    		 RCTanticoagulation, intermediate prophylactic dosecontrolCOVID-19 severe or criticallysome concern
    		276/286 inconclusive
    • inconclusive 7 % increase in Thromboembolic events (PE) with a moderate degree of certainty due to some concern in risk of bias
    REMAP-CAP, ACTIV-4a, ATTACC (critically ill patients)
          NCT02735707    		 RCTanticoagulant, curative dosecontrolCOVID-19 severe or criticallysome concern
    		591/616 inconclusive
    • inconclusive 17 % decrease in clinical improvement (PE) with a moderate degree of certainty due to some concern in risk of bias
    4 studies excluded by filtering options (0 RCT / 4 OBS)

    PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
    Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

     

    - About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons